… impact on preventing and treating chronic liver diseases [56]. … The study predicted
pharmacokinetic interactions between … , and vinflunine are also spot-highlighted and gained …

… 14 months [Citation4,Citation5]. Historically, vinflunine or taxane chemotherapy was the
most … endpoints will include PFS, ORR, as well as quality of life and pharmacokinetic studies. …

… warranted if the patient has hepatic dysfunction. Vindesine is … Vinflunine: This is currently
being employed in metastatic or … of pharmacokinetic parameters exists following intravenous …

… the safety, pharmacokinetics, and efficacy of patients with mUC with severe renal … study
evaluating EV compared with investigator choice of docetaxel, paclitaxel, or vinflunine in patients …

… pharmacokinetic analysis including 369 phase I/II patients … CPI therapy or had metastatic
liver disease, EV achieved an … , paclitaxel, or vinflunine) in patients with previously treated …

… antitumor activity and a pharmacokinetic profile consistent with prior reports. … phase III
trial of EV versus chemotherapy (docetaxel, paclitaxel, or vinflunine [EU only]) in patients with …

… Vinflunine stands out with enhanced potency and reduced adverse events, particularly in the
context of treating transitional cell urothelial bladder cancer… function, liver dysfunction, and …

… Phase III trials for second-line therapy of mUCB. The first was a report in 2009 from the Phase
III trial of vinflunine, a … Citation67 The study was designed to compare OS of UC patients …

… NCCN and ESMO guidelines have been taxanes and vinflunine (approved in the European
Union). … in the ongoing phase III confirmatory trial of SG versus taxane or vinflunine in mUC (…

… In summary, vinflunine is an active drug for second-line treatment of mUC … study was similar
to data reported in the landmark randomised phase III trial comparing vinflunine with BSC [4]. …